L2 Asset Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

L2 Asset Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-14,153	Closed	-$32K	–	85
2020 Q3	$32K	Hold	14,153	–	–	0.03%	76
2020 Q2	$51K	Hold	14,153	–	–	0.05%	62
2020 Q1	$54K	Hold	14,153	–	–	0.06%	70
2019 Q4	$43K	Buy	+14,153	New	+$36.8K	0.04%	76

Other funds holding BMY.RT

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BFS

Bard Financial Services Branford, Connecticut $911M AUM 19.14% 1-Year Est. Return

LGP

Leonard Green & Partners Los Angeles, California $2.77B AUM 3.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

L2 Asset Management's BMY.RT Position: Q4 2020 in Review

L2 Asset Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 14,153 shares — an estimated $32K sold.

L2 Asset Management first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $54K in Q1 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

L2 Asset Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
L2 Asset Management sold 14,153 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $32K.
L2 Asset Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
L2 Asset Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $54K in Q1 2020.
546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on L2 Asset Management's 13F filing for Q4 2020, filed 12 Feb 2021.